Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 12/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 9/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 9/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 9/20 | 1.00 |
| ▸ | JAK1 | P23458 | 7/20 | 1.00 |
| ▸ | TYK2 | P29597 | 7/20 | 1.00 |
| ▸ | JAK3 | P52333 | 6/20 | 1.00 |
| ▸ | JAK2 | O60674 | 5/20 | 1.00 |
| ▸ | CDK2 | P24941 | 5/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 3/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 2/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 2/20 | 1.00 |
| ▸ | CLK1 | P49759 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726847 | 0.93 | CDK1 (0.86) | CDK1CCNB2CCNB1CCNB3JAK1 | |
| SCHEMBL5725430 | 0.91 | CDK1 (0.84) | CDK1CCNB2CCNB1CCNB3JAK1 | |
| SCHEMBL5110157 | 0.91 | CDK1 (0.83) | CDK1CCNB2CCNB1CCNB3JAK1 | |
| SCHEMBL5964716 | 0.91 | CDK1 (0.83) | CDK1CCNB2CCNB1CCNB3JAK1 | |
| SCHEMBL5727451 | 0.89 | CDK1 (0.80) | CDK1CCNB2CCNB1CCNB3JAK1 | |
| SCHEMBL5727313 | 0.89 | CDK1 (0.80) | CDK1CCNB2CCNB1CCNB3JAK1 | |
| SCHEMBL5727275 | 0.88 | CDK1 (0.79) | CDK1CCNB2CCNB1CCNB3JAK1 | |
| SCHEMBL7092328 | 0.88 | CDK1 (0.78) | CDK1CCNB2CCNB1CCNB3JAK1 | |
| SCHEMBL5726691 | 0.88 | CDK1 (0.78) | CDK1CCNB2CCNB1CCNB3JAK1 | |
| SCHEMBL5725974 | 0.88 | CDK1 (0.78) | CDK1CCNB2CCNB1CCNB3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| US-12251404-B2 | Methods and compositions to maintain stem cell quiescence | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-03-18 | — | — | US | claimed |
| WO-2025051337-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ORAL CANCER | Afyx Development A/S (DK) | 2025-03-13 | — | — | WO | claimed |
| US-20250011425-A1 | COMPOSITIONS AND METHODS FOR IMPROVED T CELLS | UNIV TEMPLE (US) | 2025-01-09 | — | — | US | claimed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | claimed |
| EP-2904000-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | Agency for Science, Technology and Research (SG) | 2015-08-12 | — | — | EP | claimed |
| WO-2014149001-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-09-25 | — | — | WO | claimed |
| WO-2014055039-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-04-10 | — | — | WO | claimed |
| EP-1809254-A2 | LYOPHILIZED LIPOSOME FORMULATIONS AND METHOD | ALZA CORPORATION (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1720843-A2 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TRIAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-15 | — | — | EP | claimed |
| US-20060110441-A1 | Lyophilized liposome formulations and method | ALZA CORPORATION | 2006-05-25 | — | — | US | claimed |
| US-20060100259-A1 | Process for the preparation of substituted triazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-11 | — | — | US | claimed |
| WO-2006050327-A2 | LYOPHILIZED LIPOSOME FORMULATIONS AND METHOD | ALZA CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| WO-2005077922-A2 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TRIAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100259-A1 | Process for the preparation of substituted triazole compounds | TESK2, MAP2K2, TESK1 | CDK1 262/4885CCNB2 1767/4885CCNB1 2552/4885 |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | TP53, MDM4, MDM2 | CDK1 178/4885CCNB2 109/4885CCNB1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.